1. Scrip
  2. >>Therapy Areas

Gazyva Succeeds In NOBILITY Lupus Nephritis Study But What Next?

 
• By Eleanor Malone

Genentech refrained from committing to further development of its CD20 inhibitor in the indication despite meeting endpoints in Phase II study.

Road_Arrows
Will Roche/Genentech proceed with Gazyva in lupus nephritis?

Genentech Inc.’s Gazyva (obinutuzumab) has met the primary endpoint in a Phase II trial studying it in adults with proliferative lupus nephritis, a severe kidney complication of the autoimmune disease systemic lupus erythematosus (SLE) for which there are no approved therapies in the US or EU.

The CD20-targeting drug, which was first approved by the US Food and Drug Administration in 2013 for chronic lymphocytic leukemia...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Genitourinary

More from Therapy Areas

Veru’s Enobosarm Market Potential Enhanced By New Obesity Data

 
• By Aakash Babu

The late-stage biotech posted results from the maintenance extension portion of its Phase IIb QUALITY trial in which enobosarm reduced weight regain and helped preserve lean mass in patients who discontinued their semaglutide weight-loss treatment.

GSK, Bharat On Shigella Vaccine Phase II Data Timelines, Malaria Vaccine Price Halving

 
• By Vibha Ravi

GSK tells Scrip about timelines for data expected from two Phase II trials for its Bharat Biotech-partnered shigella vaccine candidate, which puts it ahead of Limmatech/Valneva. Meanwhile, a global-first malaria vaccine, also partnered with Bharat, sees an over 50% price cut

Pfizer’s Hympavzi Poised For Broader Hemophilia Label

 
• By Alaric DeArment

The drugmaker announced positive topline results for the drug in hemophilia A and B patients with inhibitors, on top of the existing approval for patients without inhibitors.